$1.14
+0.04
(+3.64%)▲
Revenue is up for the last 2 quarters, 20.10M → 21.46M (in $), with an average increase of 6.3% per quarter
Netprofit is down for the last 3 quarters, -7.35M → -44.55M (in $), with an average decrease of 160.9% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 34.6% return, outperforming this stock by 127.0%
0.0%
Downside
Day's Volatility :10.24%
Upside
10.24%
7.89%
Downside
52 Weeks Volatility :93.6%
Upside
93.05%
Period | Flora Growth Corp | Sector (Consumer Staples) | Index (Russel 2000) |
---|---|---|---|
3 Months | -55.29% | -6.5% | 0.0% |
6 Months | -74.21% | -6.4% | 0.9% |
1 Year | -92.4% | -0.4% | 3.1% |
3 Years | -98.81% | 7.9% | 17.1% |
Market Capitalization | 24.9M |
Book Value | $1.59 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -11.11 |
Wall Street Target Price | 20.0 |
Profit Margin | -116.79% |
Operating Margin TTM | -34.56% |
Return On Assets TTM | -25.56% |
Return On Equity TTM | -180.77% |
Revenue TTM | 64.8M |
Revenue Per Share TTM | 12.12 |
Quarterly Revenue Growth YOY | 140.0% |
Gross Profit TTM | 2.4M |
EBITDA | -19.1M |
Diluted Eps TTM | -11.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.6 |
EPS Estimate Next Year | -1.4 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 1654.39%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 106.0K | - |
Net Income | -14.2M | - |
Net Profit Margin | -13.4K% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 9.0M | ↑ 8371.7% |
Net Income | -21.2M | ↑ 49.96% |
Net Profit Margin | -236.63% | ↑ 13131.29% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 37.2M | ↑ 313.93% |
Net Income | -52.6M | ↑ 147.68% |
Net Profit Margin | -141.59% | ↑ 95.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.8M | - |
Net Income | -7.4M | - |
Net Profit Margin | -68.35% | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.1M | ↓ 13.16% |
Net Income | -12.8M | - |
Net Profit Margin | -63.75% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.5M | ↑ 6.73% |
Net Income | -44.6M | ↑ 247.58% |
Net Profit Margin | -207.62% | ↓ 143.87% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2M | - |
Total Liabilities | 2.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 19.5M | ↑ 1558.49% |
Total Liabilities | 3.2M | ↑ 29.21% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 85.5M | ↑ 339.44% |
Total Liabilities | 8.5M | ↑ 166.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 81.0K | ↓ 99.91% |
Total Liabilities | 24.6K | ↓ 99.71% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 79.1M | - |
Total Liabilities | 16.6M | - |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 73.1M | ↓ 7.5% |
Total Liabilities | 19.0M | ↑ 14.27% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 81.0K | ↓ 99.89% |
Total Liabilities | 24.6K | ↓ 99.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 77.0M | ↑ 95026.38% |
Total Liabilities | 23.4M | ↑ 95232.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.5M | ↓ 60.44% |
Total Liabilities | 20.3M | ↓ 13.56% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -544.8K | - |
Investing Cash Flow | -517.2K | - |
Financing Cash Flow | 1.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.4M | ↑ 1445.7% |
Investing Cash Flow | -2.2M | ↑ 318.41% |
Financing Cash Flow | 25.8M | ↑ 2040.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.6M | ↑ 145.2% |
Investing Cash Flow | -14.6M | ↑ 572.37% |
Financing Cash Flow | 58.1M | ↑ 125.08% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↓ 29.54% |
Investing Cash Flow | -8.1M | ↑ 72.5% |
Financing Cash Flow | -258.0K | ↓ 101.18% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↑ 0.0% |
Investing Cash Flow | -8.1M | ↑ 0.0% |
Financing Cash Flow | -258.0K | ↑ 0.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.3M | ↓ 36.11% |
Investing Cash Flow | -157.0K | ↓ 98.06% |
Financing Cash Flow | -415.0K | ↑ 60.85% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Flora Growth Corp | -46.23% | -74.21% | -92.4% | -98.81% | -98.81% |
![]() Neurocrine Biosciences Inc. | 8.03% | 19.76% | 12.28% | 18.54% | -6.09% |
![]() Haleon Plc Spon Ads | -2.66% | -0.74% | 34.62% | 8.64% | 8.64% |
![]() Zoetis Inc. | -6.58% | 5.84% | 14.72% | 8.28% | 90.78% |
![]() Viatris Inc. | -12.5% | 0.63% | 9.85% | -41.31% | -41.31% |
![]() Catalent, Inc. | 0.31% | -30.55% | -39.95% | -45.57% | 0.5% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Flora Growth Corp | NA | NA | NA | -1.6 | -1.81 | -0.26 | 0.0 | 1.59 |
![]() Neurocrine Biosciences Inc. | 63.7 | 63.7 | 1.87 | 2.36 | 0.11 | 0.08 | 0.0 | 18.99 |
![]() Haleon Plc Spon Ads | 23.82 | 23.82 | NA | 0.0 | 0.06 | 0.04 | 0.01 | 3.56 |
![]() Zoetis Inc. | 37.16 | 37.16 | 3.53 | 5.45 | 0.48 | 0.14 | 0.01 | 10.04 |
![]() Viatris Inc. | 7.07 | 7.07 | NA | 2.97 | 0.09 | 0.03 | 0.04 | 17.38 |
![]() Catalent, Inc. | 211.02 | NA | 1.18 | 1.01 | -0.05 | 0.0 | 0.0 | 25.61 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Flora Growth Corp | Buy | $24.9M | -98.81% | NA | -116.79% |
![]() Neurocrine Biosciences Inc. | Buy | $11.2B | -6.09% | 63.7 | 10.54% |
![]() Haleon Plc Spon Ads | Buy | $37.9B | 8.64% | 23.82 | 10.78% |
![]() Zoetis Inc. | Buy | $81.4B | 90.78% | 37.16 | 26.92% |
![]() Viatris Inc. | Hold | $13.0B | -41.31% | 7.07 | 11.88% |
![]() Catalent, Inc. | Buy | $8.2B | 0.5% | 211.02 | -5.43% |
Mirae Asset Global Investments (Korea) Co Ltd
Vident Investment Advisory, LLC
Renaissance Technologies Corp
UBS Group AG
Royal Bank of Canada
TOWNSQUARE CAPITAL LLC
Flora Growth Corp’s price-to-earnings ratio stands at None
Read Moreat flora growth corp. (flora), we are building the world’s largest and lowest cost vertically-integrated producer of organic cannabis and pharmaceutical-grade medical products as well as cbd-based consumer products.
Organization | Flora Growth Corp |
Employees | 337 |
CEO | Mr. Luis Merchan |
Industry | Healthcare |